# How to Pick the Best Cancer Proteins for a Vaccine

> This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components.

- **Patent:** US 20250244311
- **Original title:** Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
- **Owner:** UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG -UNIVERSITÄT MAINZ
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, oncology, immunotherapy, personalized_medicine

## What it does

The patent describes a method for making vaccines, especially for personalized cancer treatment. It involves identifying specific proteins or protein pieces from diseased cells that would be useful for immunotherapy. This identification step, as per claim 20, checks for one or more of three things: (a) if the body already has antibodies against these proteins, (b) if these proteins bind to a cell structure called F-actin, or (c) if they bind to RNA. If any of these conditions are met, it suggests the protein or its genetic code is a good candidate for a vaccine. The method then involves manufacturing a vaccine containing these selected proteins or their genetic instructions. For example, if a patient's tumor cells express a unique protein that the patient's immune system has already started to make antibodies against, that protein would be selected for inclusion in a personalized vaccine (claim 20a).

## What it does NOT cover

- Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.
- Does not cover methods for making vaccines that do not involve determining these specific binding or response properties of the proteins.
- Does not cover vaccines made from proteins that are not expressed by diseased cells, as specified in claim 20.
- Does not cover general vaccine manufacturing processes that do not incorporate this specific protein selection methodology.
- Does not cover immunotherapy approaches that do not involve a vaccine, such as direct antibody infusions or CAR-T cell therapy.

## The clever bit

The novelty lies in using specific indicators—an existing antibody response, or the binding of a protein to F-actin or RNA—as a way to predict which tumor proteins will be most effective at triggering an immune response when used in a vaccine. This moves beyond simply identifying tumor-specific proteins to selecting those with a higher likelihood of being "useful for immunotherapy" (claim 20).

## Real-world examples

1. Personalized mRNA cancer vaccines
2. Neoantigen-based cancer immunotherapies
3. Vaccines for solid tumors
4. Individualized cancer treatment plans

## Why it matters

This patent is significant for the field of personalized cancer immunotherapy. By providing a specific method to identify highly immunogenic (immune-stimulating) proteins from a patient's own tumor, it aims to improve the effectiveness of cancer vaccines. This approach could lead to vaccines that are precisely tailored to an individual's unique cancer, potentially reducing side effects and increasing treatment success compared to more general cancer therapies.

## Frequently asked questions

### What does How to Pick the Best Cancer Proteins for a Vaccine cover?

This patent describes a method for choosing specific proteins from diseased cells, like cancer cells, to create personalized vaccines by checking if the body already reacts to them or if they bind to certain cell components.

### Who owns patent US 20250244311?

This patent is owned by UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG -UNIVERSITÄT MAINZ.

### When does this patent expire?

This patent is expected to expire on October 18, 2044, when the invention enters the public domain.

### What problem does this patent solve?

This patent is significant for the field of personalized cancer immunotherapy. By providing a specific method to identify highly immunogenic (immune-stimulating) proteins from a patient's own tumor, it aims to improve the effectiveness of cancer vaccines. This approach could lead to vaccines that are precisely tailored to an individual's unique cancer, potentially reducing side effects and increasing treatment success compared to more general cancer therapies.

### What does this patent NOT cover?

Does not cover selecting vaccine components solely based on their presence in diseased cells without checking for antibody response, F-actin binding, or RNA binding.

**Full plain-English explainer:** https://patentbrief.org/patent/us/20250244311/methods-for-predicting-the-usefulness-of-proteins-or-protein-fragments-for-immun

**Original patent:** https://patents.google.com/patent/US20250244311

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Training Immune Cells to Fight Cancer Using Specific Markers](https://patentbrief.org/patent/us/10377797/cell-epitopes-and-combination-of-cell-epitopes-for-use-in-the-immunotherapy-of-m) — This patent describes a method to create a powerful immune response against cancer by taking a patient's own T cells, teaching them to recognize specific cancer markers outside the body, and then putting them back to kill cancer cells.
- [How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer](https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca) — This patent describes methods to fight various cancers by using a specific protein fragment (peptide LYHDIFSRL) to train a patient's immune cells to recognize and attack tumor cells.
- [New Peptide Vaccines for Fighting Cancer](https://patentbrief.org/patent/us/12734225/fusion-peptide-vaccines) — This patent describes new protein fragments, called polypeptides, designed to help the body's immune system fight specific cancers like lung, stomach, and skin cancer.
- [How a Specific Peptide Can Train Your Immune System to Fight Cancer](https://patentbrief.org/patent/us/12006349/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-tu-12006349) — This patent describes a specific nine-amino-acid peptide, ALFETLIQL, and its use in compositions to help the immune system's T cells recognize and attack tumor cells.
- [Training Immune Cells to Fight Specific Cancers](https://patentbrief.org/patent/us/11401319/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-esophageal-11401319) — This patent describes a method to treat certain cancers, like esophageal cancer, by training a patient's own immune cells in the lab to recognize and kill cancer cells that have specific protein markers.
